According to the new market research “Sepsis Diagnostics Market by Technology (Microbiology, Molecular Diagnostic, Immunoassay, Biomarkers), Product (Blood Culture Media, Instruments), Method (Automated), Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End-User – Global Forecast to 2023″, analyzes and studies the major market drivers, restraints/challenges, and opportunities. The global sepsis diagnostics market was valued at USD 367.9 Million in 2017 and is expected to reach USD 613.9 Million by 2023, at a CAGR of 9.1% during the forecast period.
The global Sepsis Diagnostics market is segmented based on product, type, method, technology and regions
On the basis of technology, the market is segmented into microbiology, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2017, the microbiology segment accounted for the largest share of the market. This share can be attributed to the low cost of microbiology techniques and the wide use of blood culture methods for the diagnosis of sepsis.
Download a PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155
Browse and in-depth TOC on in “Sepsis Diagnostics Market ”
120 – Tables
39 – Figures
147 – Pages
On the basis of products, the global sepsis diagnostics market is segmented into blood culture media, assays & reagents, instruments, and software. The blood culture media segment is estimated to command the largest share of the global market in 2018. The large share of this segment can be attributed to the increasing use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis.
On the basis of methods, the market is categorized into two segments, namely, conventional diagnostics and automated diagnostics. The automated diagnostics segment is expected to grow at the highest CAGR from 2018 to 2023. Accurate detection of positive blood cultures, quick turnaround time, and reduced risk of contamination is contributing to the growth of this segment.
On the basis of test type, the market is further segmented into laboratory tests and point-of-care tests. The laboratory tests segment is estimated to account for the largest share of the market in 2018. The large share of this segment can be attributed to the high use of conventional blood culture tests for sepsis diagnosis, lack of awareness about POC sepsis diagnostic tests, and low cost of laboratory testing services.
Request Free Sample Report @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=92673155
Geographically, the sepsis diagnostic market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia Pacific is expected register highest growth during the forecast period, owing to the growing prevalence of sepsis in APAC countries, rising focus of global players in this region, developing healthcare infrastructure, and rising government support for sepsis-related research.
Market Players
The key players in the Sepsis Diagnostics market are bioMérieux (France), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), Abbott (US), Roche (Switzerland), Danaher (US), Becton, Dickinson, and Company (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), and Mitsubishi Chemical Europe (Germany).
View Complete Press Release @
https://www.marketsandmarkets.com/PressReleases/sepsis-diagnostic.asp
